New cataract surgery combination gel impressive

Article

A chloramphenicol 0.25%-betamethasone 0.13% (C&B) gel combination has comparable efficacy and tolerance and better acceptance by patients than an aqueous tobramycin 0.3%-dexamethasone 0.1% (T&D) preparation for controlling inflammation and prophylaxis of endophthalmitis following cataract surgery.

A chloramphenicol 0.25%-betamethasone 0.13% (C&B) gel combination has comparable efficacy and tolerance and better acceptance by patients than an aqueous tobramycin 0.3%-dexamethasone 0.1% (T&D) preparation for controlling inflammation and prophylaxis of endophthalmitis following cataract surgery, according to the results of a study published in the September/October issue of the European Journal of Ophthalmology.

Fabrizio Camesasca and colleagues from the Italian Betamethasone-Chloramphenicol versus Dexamethasone-Tobramycin Combination study group conducted a prospective, randomized clinical trial of patients with bilateral operative cataract. Postoperatively, for 15 days, one eye was randomly assigned to therapy with the C&B combination three times a day (Group 1) and the other to the T&D combination eye-drops four times a day.

A total of 142 patients (284 eyes) completed the study. The two groups were comparable with regards efficacy, side effects, uncorrected visual acuity, intraocular pressure, oedema or hyperemia of the eyelids, decreased corneal transparency, corneal oedema, Descemet folds, anterior chamber Tyndall and depth and posterior synechiae. Postoperative subjective pain and dry eye sensation were also comparable but the C&B gel combination elicited a significantly more pleasant sensation in patients (p=0.04).

The authors believe that the superior patient acceptance of the C&B gel combination will improve patient compliance and therefore help decrease potential side effects from cataract surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.